Fevipiprant
Fevipiprant is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against prostaglandin D2 receptor 2.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | 6 | 6 | — | — | 12 |
| Nasal polyps | D009298 | HP_0100582 | J33 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Eosinophilia | D004802 | HP_0001880 | D72.1 | — | 1 | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | — | — | — | 1 |
| Allergic rhinitis | D065631 | J30.9 | — | 1 | — | — | — | 1 | |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | FEVIPIPRANT |
| INN | fevipiprant |
| Description | Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2).
|
| Classification | Small molecule |
| Drug class | prostaglandin receptor antagonists, non prostinoid structure |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1C(F)(F)F |
Identifiers
| PDB | — |
| CAS-ID | 872365-14-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3137332 |
| ChEBI ID | — |
| PubChem CID | 23582412 |
| DrugBank | DB12011 |
| UNII ID | 2PEX5N7DQ4 (ChemIDplus, GSRS) |
Target
Agency Approved
PTGDR2
PTGDR2
Organism
Homo sapiens
Gene name
PTGDR2
Gene synonyms
CRTH2, DL1R, GPR44
NCBI Gene ID
Protein name
prostaglandin D2 receptor 2
Protein synonyms
CD294, chemoattractant receptor homologous molecule expressed on T helper type 2 cells, Chemoattractant receptor-homologous molecule expressed on Th2 cells, G-protein coupled receptor 44, putative G-protein coupled receptor 44
Uniprot ID
Mouse ortholog
Ptgdr2 (14764)
prostaglandin D2 receptor 2 (Q9Z2J6)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 173 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more